Between 1980 and 1999, 25 patients with chronic lymphocytic leukemia (CLL) received related donor hematopoietic stem cell transplants. Median patient age was 46.6 years. Preparative regimens included busulfan (BU) plus cyclophosphamide (CY), CY plus TBI, and etoposide, CY plus TBI. Twenty-one donors were HLAidentical siblings, one was a DR mismatched sibling, and three were identical twins. Bone marrow was the source of hematopoietic stem cells in 22 cases and G-CSF stimulated peripheral blood in three cases. Most patients received methotrexate and cyclosporine for GVHD prophylaxis. Fourteen patients developed grades 2-4 acute GVHD and 10 developed clinical extensive chronic GVHD. Late clearance of CLL cells was associated with the development of chronic GVHD in one patient. Two patients had recurrent CLL. Nonrelapse mortality at day 100 was 57% for the seven patients conditioned with BU/CY and 17% for the 18 patients conditioned with TBI-containing regimens. Actuarial survival at 5 years for the 25 patients is 32%. All patients who received BU/CY died within 3 years of transplant. For the 14 patients transplanted since 1992 and who received TBI, actuarial 5-year survival is 56%. The maximum response of CLL to hematopoietic cell transplantation may be delayed, but long-term diseasefree survival can be achieved.
Corresponding improvement in survival, however, has not been proven. 1 Characterized as an illness of the elderly, which may never be life-threatening, CLL has often been regarded as a disease for which aggressive therapy is not indicated.
Interest in autologous and allogeneic hematopoietic stem cell transplantation to treat CLL has been spurred both by younger patients seeking cure of their disease and by patients who have become refractory to chemotherapy, including fludarabine. Newer treatment approaches with monoclonal antibodies such as Campath-I and rituximab, while promising, do not appear to be curative. [2] [3] [4] Because of the small number of CLL patients transplanted to date, factors associated with improved survival and potential cure of disease are not well defined. This retrospective analysis summarizes the results of related donor hematopoietic stem cell transplantation for CLL at a single institution. Variability in time to achieving maximal response and the potential importance of the conditioning regimen and supportive care are emphasized.
Patients and methods

Patient characteristics
Between February 1980 and December 1999, 25 patients with CLL received hematopoietic stem cell transplants from related donors. Seventeen patients were male, eight were female. Median patient age was 46.6 years (range, 14.5-59.4 years). Twenty-one patients had B-CLL by phenotyping criteria; four patients had no phenotyping studies done, but morphologically had disease consistent with B-CLL. Of the 19 patients who had cytogenetic analyses performed prior to transplant, 10 had a normal karyotype. The most frequent clonal abnormality was trisomy 12, occurring in three patients. One patient with B-CLL had progressed to Richter's syndrome prior to transplant and one patient had evolved to CLL with increased prolymphocytes. Patients received a median of four different chemotherapy regimens. Nineteen patients had received a least one cycle of fludarabine: 12 had progressive disease, two had stable disease, three had responsive disease, and two had fludarabine discontinued because of complications to therapy. One patient had undergone splenectomy, but no patient had received radiation therapy. Prior to transplant, 16 patients had refractory or progressive disease, eight had disease responsive to the most recent chemotherapy, and one patient had stable disease. Median disease duration prior to transplant was 5.1 years (range, 1.2-16.5 years). At the time of transplant, 16 patients had stage IV disease by the Rai classification, one had stage III, six had stage II, one had stage I, and one had stage 0 disease. 5 Patient characteristics are summarized in Table 1 .
Informed consent was obtained from all patients and donors using forms approved by the Institutional Review Board of the Fred Hutchinson Cancer Research Center. Patients were transplanted at the Fred Hutchinson Cancer Research Center (n ϭ 20), the University of Washington Medical Center (n ϭ 1), or the Veterans Administration Medical Center in Seattle (n ϭ 4). Male  17  6  11  Female  8  1  7  Rai stage at diagnosis  0  4  2  2  I  5  0  5  I I  4  2  2  III  5  0  5  I V  3  0  3  Unknown  4  3  1  Karyotype  Normal  10  3  7  +1 2  3  1  2  Other  6  3  3  No data  6  0 0  1  0  1  I  1  0  1  I I  6  3  3  III  1  0  1  IV  16  4  12  Binet stage pre transplant  A  5  3  2  B  6  0  6  C  1 4  4  1 0 Numbers in columns refer to numbers of patients unless otherwise specified. a Non-TBI patients ϭ patients whose conditioning regimen did not include total body irradiation (TBI). b TBI patients ϭ patients whose conditioning regimen included TBI.
Transplant regimen
The two major preparative regimens used included BU, ). Day 0 was defined as the day of BM or PBSC infusion.
Of the 22 non-twin transplant recipients, 15 received MTX and CsA for GVHD prophylaxis. 7 Additional regimens used in small numbers of patients are noted in Table 2 .
Neutrophil engraftment was defined as the first day of a sustained absolute neutrophil count Ͼ0.5 ϫ 10 9 /l and platelet engraftment was defined as the first day of a sustained, untransfused platelet count Ͼ20 ϫ 10 9 /l. IWCLL criteria, plus appropriate flow cytometric, cytogenetic, and chimerism data, as available, were used to define response to therapy. 8 Chimerism studies were available for nine patients and included molecular cytogenetics using fluorescence in situ hybridization (FISH) for patients who had sex mismatched donors and analysis of variable nucleotide tandem repeat (VNTR) loci for patients with same-sex donors. 9 Molecular studies for detection of minimal residual disease using the Ig V H rearrangement were not routinely performed during the time period of this study. 10, 11 The severity of acute and chronic GVHD was assessed according to previously published criteria. 12, 13 Treatment of acute GVHD varied with time, depending on active protocols: primary therapy included single-agent or combination therapy with prednisone, increased doses of CsA, horse anti-thymocyte globulin (ATG), or psoralen plus ultraviolet light therapy (PUVA).
14 Therapy for chronic GVHD also varied over time and included CsA, CsA plus prednisone, azathioprine, and PUVA. 15 
Supportive care
Patients received transfusions with irradiated red blood cells for a hematocrit р0.25 while an inpatient and р0.27 while an outpatient. Irradiated platelet transfusions were administered for platelet counts р20 ϫ 10 9 /l when patients were hospitalized, and р10-20 ϫ 10 9 /l when patients were outpatients and there were no signs of active bleeding. Blood products from CMV serologically negative donors 819 Table 2 Transplant data Numbers in columns refer to numbers of patients unless otherwise specified. ATG ϭ horse anti-thymocyte globulin.
were provided to patients who were CMV negative by serologic testing pretransplant. Patients who had an absolute neutrophil count Ͻ0.5 ϫ 10 9 /l and whose temperature exceeded 38.5°C were empirically treated with broad-spectrum anti-bacterial antibiotics. Trimethoprim/sulfamethoxazole was used for PCP prophylaxis prior to transplant, and after engraftment until completion of all immunosuppressive therapy. Dapsone was given to patients who were allergic to sulfa. Beginning in the mid-1980s, patients who were herpes simplex virus positive pretransplant by serologic testing received acyclovir during their transplant course. Beginning in January 1999, patients who were varicella zoster virus positive received acyclovir for 1 year after transplant. By 1992, patients without active fungal infection received prophylactic fluconazole to day 75 and patients who became CMV antigenemia positive received ganciclovir or foscarnet. 16, 17 Prophylactic intravenous immunoglobulin (IVIg) therapy was also initiated in 1992. Between 1992 and 1997, patients received 500 mg/kg IVIg i.v. weekly from admission until approximately day 100. Since 1997, patients received Bone Marrow Transplantation prophylactic IVIg only as necessary to maintain their serum IgG level Ͼ400 g/l.
Statistical analysis
Survival probabilities were estimated using the KaplanMeier method. 18 Log-rank testing was done to test for differences between survival curves.
Results
Engraftment
Of the 22 patients evaluable for neutrophil engraftment, the median time to achieving an ANC Ͼ0.5 ϫ 10 9 /l was day 20 (range, day 6-32). The remaining three patients died between 16 and 25 days after transplant. Of the 21 patients who became platelet transfusion independent, the median time to achieving a platelet count Ͼ20 ϫ 10 9 /l was day 18 (range, day 9-73).
Toxicity
Veno-occlusive disease (VOD) occurred in 11 patients and renal failure in six. VOD occurred more frequently in those patients who received the BU/CY conditioning regimen. Six of seven patients who received BU/CY developed VOD, compared to five of 18 patients who received a CY/TBI regimen (P ϭ 0.021).
Acute GVHD was diagnosed in 18 patients at a median time of 21 days after transplant. Fourteen of these 18 patients developed у grade 2 GVHD requiring therapy. Of the 18 patients who survived at least 80 days, 10 developed clinical extensive chronic GVHD, at a median time of day 100. Sixteen of 19 patients who received fludarabine prior to transplant were evaluable for acute GVHD: 11 developed acute GVHD requiring therapy, compared to three of six evaluable patients who did not receive fludarabine (P ϭ 0.45).
Response to therapy
Seventeen patients had at least one restaging study performed between days 15 and 390 (median, day 77) after transplant: 13 achieved a CR by marrow morphology and six of seven evaluable patients achieved a CR by flow cytometric studies. All nine patients who had chimerism studies performed achieved 100% donor engraftment. The variation in time to response is depicted in Figure 1 . Five of 16 evaluable patients had evidence of persistent morphologic disease у90 days after transplant. Two of these five patients subsequently achieved morphologic CR. One of the five (UPN 11917) had persistent morphologic evidence of CLL cells for 2 years after transplant, despite normal flow cytometric and chimerism studies after the development of chronic GVHD.
One patient (UPN 10296) failed to clear her CLL cells after receiving stem cells from a syngeneic donor. Two patients (UPN 01143 and 04382) had recurrent CLL after an initial response. UPN 01143 recurred after a syngeneic transplant and had a second transplant from the same donor 3 years after the first, using a conditioning regimen of CY + 8 Gy TBI. She again relapsed almost 2 years after her second transplant. UPN 04382 relapsed 9 months after transplant from an HLA-identical sibling, rapidly developing stage IV disease. He had an initial response to fludarabine, but died 1 year later with persistent CLL.
Late complications
One patient developed a second malignancy. UPN 9916 developed renal cell carcinoma 9 months after transplant and underwent a nephrectomy. He has no known evidence of recurrent disease.
Survival
Eight patients are surviving a median of 39.2 months (range, 9.5-101.9 months) and 17 patients died at a median time of 139 days (range, 16-1906 days) after transplant. Actuarial 5-year survival for all 25 patients is 32%. Of the seven patients who received the BU/CY preparative regimen, all died within 3 years of transplant. For the 18 patients who received a TBI-containing regimen, actuarial survival at 5 years is 48% (Figure 2 ). For the 14 patients who received a TBI-containing regimen and who were transplanted since 1992, actuarial survival at 5 years is 56% (Figure 3) . Sixteen of the 25 patients had stage IV disease pretransplant and nine had stages 0-III. Actuarial 5-year survival for the stage IV patients is 25%, compared to 44% for the nine patients with lower tumor burdens (P ϭ 0.15).
Causes of death are summarized in Table 3 . Of the seven patients who received BU/CY, four died Ͻ100 days after transplant and two died between days 100 and 150. Of the 18 patients who received a TBI-containing preparative regimen, only three died before day 100 and one died between days 100 and 150.
Discussion
Based on the results of HCT in acute leukemia and lymphoma patients, tumor burden and disease duration would be expected to be important factors affecting the outcome of transplantation for CLL. The majority of our patients had stage IV disease and were heavily pretreated. When comparing the nine patients who had stages 0-III disease to the 16 with stage IV disease, improved survival was seen in patients with lower tumor burdens (44% vs 25% at 5 821 Table 3 Results years, respectively). This difference in survival is not statistically significant (P ϭ 0.15). Improved survival was also not significantly associated with being transplanted earlier in the course of the disease (Ͻ5 years vs у5 years, P ϭ 0.42). However, the relatively small numbers of patients available for study limits the power of these analyses. Survival after HCT is also associated with transplantrelated mortality and relapse post transplant. Initially, patients with CLL transplanted at this center were prepared for transplant with a CY/TBI regimen. Because of encouraging phase I results in multiple myeloma patients transplanted with a BU/CY regimen, in 1992 this chemotherapyonly regimen was adapted for patients with CLL who had HLA-identical related donors. 19 As seen in Table 1 , patients who did and did not receive TBI had similar pretransplant characteristics. Unexpectedly, six of the seven patients who received the BU/CY regimen died р150 days after transplant from a variety of nonrelapse-associated causes (infection 2, acute GVHD 1, multi-organ failure 2, multiple thromboses 1). Reasons for this high early mortality are unclear; however, busulfan pharmacokinetics to target dose levels were not available and high BU levels could have played a role in the two deaths from multi-organ failure. 20 Additionally, a higher dose of CY (150 mg/kg) was used in this study. Because of this unacceptable high early morBone Marrow Transplantation tality, a CY/TBI preparative regimen was reinstituted. Death before day 150 occurred in only one of the 10 more recent patients conditioned with CY/TBI.
All patients
Decreased transplant-related mortality may, in part, be related to improvement in supportive care, thereby decreasing life-threatening infection. Morbidity and mortality from both HSV and VZV infections have been virtually eliminated with the institution of prophylactic acyclovir. Similarly, the prophylactic use of anti-fungal agents such as fluconazole or itraconazole has significantly reduced the incidence of many systemic fungal infections, especially Candida species infections. 16 In those CLL patients who have associated hypogammaglobulinemia, the administration of intravenous immunoglobulin to maintain normal IgG levels may also play a role in prevention of infection. An apparent increase in survival (56% at 5 years) was seen in our patient population who received a TBI-containing preparative regimen and who were transplanted after these supportive care measures were implemented. Much larger numbers of patients are needed to assess the magnitude of this contribution. Based on the recent results of a prospective, randomized study comparing PBSC collection to marrow harvest in allogeneic HCT recipients, the institution of PBSC as the preferred source of stem cells may also help to decrease morbidity and mortality from infections in patients with advanced disease. 21 The role of a graft-versus-leukemia (GVL) effect in CLL patients in improving survival has been reported. [22] [23] [24] Persistence of CLL cells during the first few months after transplant should not be regarded as ominously as the persistence of leukemic cells in patients undergoing HCT for acute leukemia. As can be seen in Figure 1 , it may take a longer period of time for CLL patients to eradicate their malignant clone of lymphocytes. Whether this prolonged time to maximum response is a reflection of the time needed for CLL cell death or the time needed to effect a GVL response is uncertain.
In our series of patients, a GVL effect was thought to play a major role in at least one patient (UPN 11917 in Figure 1 ) who only achieved a complete remission based on chimerism studies and flow cytometric data after prolonged chronic extensive GVHD. Prior to transplant, this patient had CLL for 13.4 years and had been treated with three different chemotherapy regimens, including fludarabine for over 7 years. He had Rai stage IV disease pretransplant, and had morphologic, cytogenetic, and flow cytometric evidence of persistent disease for at least 1 year post transplant.
With the advent of molecular testing for minimal residual disease by determining the Ig V H gene mutation status, the ability to 'cure' CLL with allogeneic transplantation will ultimately be determined. Patients with unmutated Ig V H genes display higher percentages of CD38 + B-CLL cells and appear to have a more aggressive form of CLL. 10, 11 Molecular testing results were not available for the CLL patients reported in this study and quantitative CD38 expression data are available for only seven patients. All five patients with Ͻ30% CD38 + CLL cells pretransplant are alive, compared to one of two patients who had у30% CD38 + CLL cells. The role of hematopoietic stem cell transplantation in the treatment of CLL continues to be defined. Encouraging autologous and allogeneic transplant results have been reported from single centers and from registry data. [25] [26] [27] [28] [29] Recent International Bone Marrow Transplant Registry analyses report 3-year survival probabilities of 49% and 87% for allogeneic and autologous transplant recipients, respectively. 30 Similar results have been reported by the European Bone Marrow Transplant Registry with a 3-year survival of 54% for allogeneic and a 2-year survival of 83% for autologous transplant recipients. 31, 32 These results for CLL patients undergoing allogeneic transplantation are similar to our results using a TBI-containing regimen with current supportive care measures.
The type of transplant recommended for patients with CLL is currently based on patients' initial response to conventional chemotherapy, availability of a suitable related or unrelated allogeneic donor, and patient age and general medical condition. Timing of such a transplant is, in large part, dependent on patients' prior response to therapy. In a large cohort of patients with CLL who received fludarabine as primary therapy, the median time to progression of disease for responding patients was 31 months. 33 Subsequent salvage therapy with combination chemotherapy (which often includes fludarabine) can yield response rates of 60-70%. Salvage treatment with single agent monoclonal antibody therapy, or combinations of antibodies plus chemotherapy, is effective in approximately 40% of patients. [2] [3] [4] However, remission durations after secondary therapy are significantly shorter than remission durations following primary therapy. Therefore, for patients with recurrent disease, especially younger patients and patients with poor prognostic features, a more aggressive approach with allogeneic HCT should be considered.
Nonmyeloablative transplants are now being explored in older patients and in patients who have medical conditions precluding consideration of a myeloablative procedure. 34 To begin evaluating the relative effectiveness of nonmyeloablative approaches, it is necessary to know what effect can be achieved with standard transplant techniques. While such comparisons will never substitute for randomized trials, they can be important in deciding whether or not it is appropriate to proceed to such trials.
